Pipeline overview

Three H Bio (3H Bio) Co., Ltd., a Korean bio-venture company established in 2019. 3H Bio develops Obesity Vaccine (3HOTP) candidate and a series of first-in-class drugs for metabolic diseases, including Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). Also, an organoid-based Developmental And Reproductive Toxicity (DART) drug-screening platform technology is under development.

3H Bio provides an exciting in-licensing opportunity for worldwide companies seeking new anti-obesity drugs and the drugs for metabolic syndromes related with lipid metabolism.

Drug development

US FDA New Animal Drug Application (NADA) milestones of 3HOTP